Detection of Phage’s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay
Infectious Diseases and Therapy · 2025-01 · 14 (1) · 217-228
DOI: 10.1007/s40121-024-01092-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infectious Diseases and Therapy, online erschienen am 22.12.2024. Verfasst von Paschalis Paranos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology Laboratory, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: The host range of phages is usually assessed with the agar overlay method. However, this method is both cumbersome and subjective. Therefore, a microbroth assay was developed to assess host range and lytic activity patterns of phages in the agar overlay method against a collection of carbapenemase-producing Klebsiella pneumoniae (CRKP) isolates. METHODS: The host range of 11 K. pneumoniae-specific phages against 8 non-repetitive well-characterized CRKP isolates was assessed with the agar overlay method and a microbroth assay by monitoring optical density (OD) at 630 nm for 24 h at different phage concentrations (5 × 109-5 × 103 PFU/ml) and two bacterial inocula (5 × 106 and 5 × 108 CFU/ml). The lytic activity of phage-bacteria pairs with transparent/semi-transparent (N = 7), turbid (N = 6), and no (N = 6) lysis in overlay agar method was compared statistically with the growth inhibition at 6 and 24 h in the microbroth assay with analysis of variance (ANOVA), receiver operating characteristic curves (ROC) curves and Fisher's exact test. Optimal cutoffs were determined, and sensitivity and specificity were calculated. RESULTS: Statistically significant differences of growth inhibition at 6 and 24 h for phage concentrations ≥ 5 × 108 PFU/ml for both inocula were found between phages with transparent/semi-transparent, turbid, and no lysis. ROC curve analysis indicated an optimal growth inhibition cutoff of ≥ 31% at high phage and bacteria concentrations for detecting phages with lysis and ≥ 61% at high-phage and low-bacteria concentrations for detecting phages with transparent/semi-transparent lysis with sensitivity/specificity 100%/100% and 100%/86%, respectively. CONCLUSIONS: The microbroth growth inhibition assay provided fast, reliable, and objective results for K. pneumoniae phage host-range lytic activity differentiating different patterns of lysis in a high-throughput format.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Microbiology Laboratory, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Clinical Microbiology Laboratory, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. jmeletiadis@med.uoa.gr.
Zitieren
APA
Paranos, P., Pournaras, S., & Meletiadis, J. (2025). Detection of Phage’s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay. Infectious Diseases and Therapy, 14(1), 217-228. https://doi.org/10.1007/s40121-024-01092-0
Vancouver
Paranos P, Pournaras S, Meletiadis J. Detection of Phage’s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay. Infectious Diseases and Therapy. 2025;14(1):217-228. doi:10.1007/s40121-024-01092-0
BibTeX
@article{Paranos2025,
author = {Paranos, Paschalis and Pournaras, Spyros and Meletiadis, Joseph},
title = {Detection of Phage’s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay},
journal = {Infectious Diseases and Therapy},
year = {2025},
volume = {14},
number = {1},
pages = {217--228},
doi = {10.1007/s40121-024-01092-0}
}
EUVIMED